Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company focused on developing thiol-based therapies for pediatric medical needs, with its lead candidate being TTI-0102. While the company shows a strong liquidity position with a current ratio of 1.31 and no debt, it faces significant concerns with a negative ROE of -415.8% and ROA of -97.9%, indicating poor profitability. The recent 21.65% price increase may reflect market optimism, but the overall financial health score of 63/100 suggests caution for potential investors.
Loading financial metrics...
Company is burning $500K per quarter with $1.8M in cash. Approximately 3.7 quarters of runway at current burn rate.
Company posted a loss of $-3.3M over the last year, representing Infinity% of revenue.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)